MARLBOROUGH, Mass. - Boston Scientific Corporation (NYSE:BSX) announced Monday the completion of a €2 billion public offering of senior notes by its finance subsidiary, American Medical Systems Europe B.V. The offering comprises €750 million of 3.375% notes due 2029 and €1.25 billion of 3.500% notes due 2032, both guaranteed by Boston Scientific.
The company has expressed intentions to allocate the net proceeds from the notes, alongside borrowings under its commercial paper program and available cash, to fund the acquisition of Axonics, Inc. The funds will also cover related fees and expenses. Any remaining proceeds may be used to repay the company's 3.450% senior notes due in March 2024, including accrued and unpaid interest, and for general corporate purposes.
Boston Scientific is a global leader in medical technology, providing solutions that address patient needs and aim to reduce healthcare costs. Its portfolio includes devices and therapies for the diagnosis and treatment of various complex diseases across multiple medical fields.
The press release also included a cautionary note about forward-looking statements, which are based on current beliefs and assumptions and are not guarantees of future performance. It highlighted potential risks and uncertainties that could cause actual results to differ materially from expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.